Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on August 28, 2015, reporting a material definitive agreement entered into on the same date. The filing concerns an Exclusive Supply Agreement and related equity transactions between ChromaDex, Inc. (a wholly owned subsidiary) and Healthspan Research, LLC.
Key Financial Metrics and Transaction Terms
The filing details a strategic partnership rather than standard financial performance metrics. Key terms include:
- Equity Stake: ChromaDex received a 9% equity interest in Healthspan Research, LLC.
- Consideration Structure:
- 4% equity interest in exchange for initial free supply of NIAGEN and subsequent fixed-price supply.
- 5% equity interest in exchange for exclusive resale rights in certain direct response channels.
- Revenue Model: Healthspan will pay royalties on cumulative worldwide net sales of finished products containing NIAGEN.
- Contract Duration: Initial term of three years with automatic one-year renewals.
- Related Party: Rob Fried, a director of ChromaDex, is the manager of Healthspan and owns 91% of its equity.
Material Changes and Agreements
The primary material change is the entry into the Supply Agreement and Purchase Agreement. Notable provisions include:
- Exclusivity Conditions: Exclusive rights are contingent on Healthspan meeting minimum purchase requirements.
- Redemption Clause: If exclusivity rights are terminated due to failure to meet purchase requirements (or reasons other than a material breach by Healthspan), the 5% equity interest is automatically redeemed for $1.00.
- Corporate Governance: The LLC Agreement includes tag-along rights, drag-along obligations, and anti-dilution provisions.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance or revenue forecasts. However, it highlights the following risks and contingencies:
- Performance Risk: The value of the 5% equity stake is contingent on Healthspan meeting minimum purchase requirements; failure to do so results in nominal redemption value.
- Termination Risk: Either party may terminate the agreement for breach or other typical reasons.
- Disclosure Limitation: Certain terms of the agreements are subject to confidential treatment and will be fully disclosed in the Form 10-Q for the quarter ended October 3, 2015.
Investor Verification Checklist
- Verify the full text of the Supply Agreement and LLC Agreement in the upcoming Form 10-Q (Q3 2015) to review confidential terms.
- Confirm the specific "minimum purchase requirements" that trigger the redemption of the 5% equity stake.
- Assess the financial impact of the related-party transaction involving director Rob Fried.
- Monitor future royalty payments and sales volume of NIAGEN products through Healthspan channels.